Sinusitis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The sinusitis treatment market size is expected to grow from USD 2.69 billion in 2025 to USD 2.85 billion in 2026 and is forecast to reach USD 3.83 billion by 2031 at 6.05% CAGR over 2026-2031. This report is Segmented by Disease (Acute Sinusitis, Sub-Acute Sinusitis, Chronic Sinusitis), Modality (Drug Class Including Analgesics, Antihistamines, Corticosteroids, Antibiotics, Others, and Minimally-Invasive Surgery), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Sinusitis Treatment Market Trends and Insights

Rising Prevalence of Chronic & Acute Rhinosinusitis

Chronic rhinosinusitis now affects up to 12% of the global population, translating to heavier outpatient loads and higher surgical referrals. COVID-related microbial shifts introduced a cohort with persistent inflammatory symptoms, raising hospital admissions for complicated sinusitis. In the United States, productivity losses average 20.6 workdays per patient per year and drive USD 8 billion in annual medical spending. Urban air pollutants and allergens intensify mucosal inflammation, magnifying demand for durable treatments across every sinusitis treatment market segment. Aging populations and longer life expectancy further solidify a multi-year volume base for biologics, image-guided surgery, and probiotic solutions.

Growing Preference for Minimally-Invasive Balloon Sinuplasty

Balloon sinuplasty has been increasing, showing how tissue-preserving techniques are displacing conventional FESS. Current evidence reports 91% clinical success with fewer postoperative complications, positioning balloon dilation as the first-line surgical option for many patients. Office-based execution cuts hospital stay and dovetails with value-based care; Stryker’s analysis shows USD 2,200 per-patient savings compared with traditional FESS, a compelling argument for payers. Image-guided navigation further improves precision, especially inside complex frontal recess anatomy, while disposable microdebriders reduce infection risk and reprocessing costs. These advantages collectively pull incremental procedure volume into the sinusitis treatment market.

Escalating Penetration of Low-Cost Generics & OTC Decongestants

Generic launches reduce average selling price of azelastine-fluticasone sprays, with U.S. retail erosion exceeding 45% within 12 months of patent expiry. OTC nasal sprays now match prescription efficacy in shortening symptom duration to 6.5 days, adding retail-channel competition. Herbal alternatives such as Sinupret allow delayed antibiotic strategies that trim antimicrobial use by 43.7% in randomized settings. In emerging economies, generics account for over 70% of total scripts, compressing branded margins and pressuring innovators to demonstrate superior outcomes. This price deflation temporarily caps revenue expansion within certain segments of the sinusitis treatment market.

Other drivers and restraints analyzed in the detailed report include:

• Expanding Access to Combination Drug Regimens
• Rapid Uptake of Biologics for CRSwNP
• Rising Antibiotic-Resistance Pressures Curbing Empirical Scripts

Segment Analysis

Chronic sinusitis controlled 57.02% of sinusitis treatment market share in 2025 thanks to its recurrent profile and higher resource utilization. The segment absorbs biologic spending and revision FESS volumes, underpinning robust revenue streams. Acute sinusitis, while smaller, is projected to expand at a 7.31% CAGR, reflecting better primary-care diagnostics and refined antibiotic protocols. Sub-acute sinusitis serves as the bridge phenotype, often migrating into chronic classification when inadequately resolved.

Chronic disease heterogeneity continues to steer precision medicine. Eosinophilic variants respond strongly to IL-4/IL-13 blockade, whereas non-eosinophilic phenotypes common in Asian populations need alternative pathways. Tissue eosinophilia scoring during surgery now guides postoperative pharmacotherapy, cutting revision risk. Parallel development of biomarkers and next-generation biologics secures long-term growth for the sinusitis treatment market size linked to chronic disease management.

Complete Report Scope:

• By Disease
  • Acute Sinusitis
  • Sub-acute Sinusitis
  • Chronic Sinusitis
• By Modality
  • Drug Class
    • Analgesics
    • Antihistamines
    • Corticosteroids
    • Antibiotics
    • Others
  • Minimally-invasive Surgery (Balloon Sinuplasty, FESS)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 39.62% of the sinusitis treatment market in 2025 due to early biologic adoption and payer support for minimally-invasive surgery. The September 2024 adolescent dupilumab approval and the June 2025 SONU Band pediatric clearance underscore an innovation-friendly regulatory climate. Balloon sinuplasty delivers USD 2,200 average savings per case compared with traditional FESS, further cementing payer backing. Canada’s rigorous pharmacoeconomic evaluations favor omalizumab as the cost-effective biologic for eligible patients. Mexico’s rising middle class and medical tourism growth broaden procedure and drug uptake, extending North American influence across the sinusitis treatment market.

Asia-Pacific registers the fastest regional CAGR at 8.02%, powered by infrastructure investment and greater awareness of advanced therapies. China demonstrates strong demand for image-guided FESS, showing 100% avoidance of rehospitalization for bleeding and lower overall cost per quality-adjusted life year versus conventional surgery. The December 2024 approval of stapokibart, China’s first indigenous biologic, marks a strategic milestone that improves access and lowers dependence on imported agents. Workforce shortages remain a drag, yet tele-mentoring and robotics partially offset skill gaps, keeping the sinusitis treatment market on a steep trajectory.

Europe shows steady expansion under tight cost-containment regimes. The European Position Paper on Rhinosinusitis supplies unified diagnostic and therapeutic criteria that drive evidence-based utilization. Major markets - Germany, United Kingdom, France - lead biologic uptake, while southern nations accelerate adoption after positive health-technology assessments. Digital health tools support remote follow-up and specialist consultations, widening reach in rural settings and stabilizing growth for the sinusitis treatment market across the continent.

List of Companies Covered in this Report:

• Acclarent Inc (J&J)
• AstraZeneca
• Aurobindo Pharma
• Bayer
• Cipla
• Dr Reddy’s Laboratories
• Entellus Medical
• GlaxoSmithKline
• Medtronic
• NeilMed Pharmaceuticals
• Novartis
• Olympus
• OptiNose Inc
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• SinuSys
• Smiths Group
• Stryker
• Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support